NON-ANTIBIOTIC USE OF ANTIBIOTICS

Publications

Share / Export Citation / Email / Print / Text size:

Postępy Mikrobiologii - Advancements of Microbiology

Polish Society of Microbiologists

Subject: Microbiology

GET ALERTS

ISSN: 0079-4252
eISSN: 2545-3149

DESCRIPTION

0
Reader(s)
0
Visit(s)
0
Comment(s)
0
Share(s)

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue / page

Related articles

VOLUME 57 , ISSUE 4 (April 2018) > List of articles

NON-ANTIBIOTIC USE OF ANTIBIOTICS

Maciej Danielewski * / Dorota Ksiądzyna / Adam Szeląg

Keywords : antibiotics, non-infectious diseases, atypical indications

Citation Information : Postępy Mikrobiologii - Advancements of Microbiology. Volume 57, Issue 4, Pages 301-312, DOI: https://doi.org/10.21307/PM-2018.57.4.301

License : (CC BY-NC-ND 4.0)

Published Online: 24-May-2019

ARTICLE

ABSTRACT

Antibiotics are widely used medicines in the treatment of infectious diseases. However, some of them show also non-antibiotic properties, which are increasingly used in the treatment of non-infectious diseases. The authors of this publication believe that this is one of the reasons behind antibiotic dissemination in the environment and, ipso facto, behind the increasing risk of bacterial resistance. It is worth remembering that, along with the progress in science and better knowledge of the new properties of antibiotics, every extension of indications for antimicrobial agents may restrict their primary indications. Progress in science does not always mean progress in therapy. In fact, it may sometimes have an opposite effect and we should be able to assess the benefit/risk ratio. The aim of this study was to present other than antibacterial properties of antibiotics which currently are or may be used in the future in the treatment of non-infectious diseases, as well as to assess the long-term effects of extending the indications for medicines commonly used in the treatment of infectious diseases. To the best of the authors’ knowledge, such attempt has not been made so far, therefore authors decided to review the most important, useful or promising reports on non-antibiotic use of antibiotics. The article summarizes the latest data on prokinetic action of erythromycin, anti-inflammatory and immunomodulatory action of azithromycine, potential use of doxycycline as an anti-cancer and anti-inflammatory agent, and also anti-inflammatory, neuroprotective, antioxidant and antiapoptotic properties of minocycline. Futhermore, the basics of demeclocycline application in the treatment of inappropriate antidiuretic hormone hypesecretion syndrome and rifaximin use as an anti-inflammatory and eubiotic agent are presented. Neuroprotective action of ceftriaxone and anti-inflammatory and immunostimulatory action of fusafungine were also described.

Content not available PDF Share

FIGURES & TABLES

REFERENCES

1. Abbaszadeh A., Darabi S., Hasanvand A., Amini-Khoei H., Abbasnezhad A., Choghakhori R., Aaliehpour A.: Minocycline through attenuation of oxidative stress and inflammatory response reduces the neuropathic pain in a rat model of chronic constriction injury. Iran. J. Basic Med. Sci. 21, 138–144 (2018)

2. Bajaj J.S., Gillevet P.M. i wsp.: Modulation of the microbiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy. PLoS ONE, 8, e60042 (2013)

3. Banh H.L.: Unconventional treatment options in severe asthma: an overview. J. Pharm. Pharm. Sci. 14, 387–399 (2011)

4. Beker B., Mujica V., Guelrud M.: Effect of erythromycin on the sphincter of Oddi in healthy volunteers. Gastroenterology, 100, A309 (1991)

5. Broad J., Sanger G.J.: The antibiotic azithromycin is a motilin receptor agonist in human stomach: comparison with erythromycin. Brit. J. Pharmacol. 168, 1859–1867 (2013)

6. Calanni F., Renzulli C., Barbanti M., Viscomi G.C.: Rifaximin: beyond the traditional antibiotic activity. J. Antibiot. 67, 667–670 (2014)

7. Carbonell N., Pauwels A., Serfaty L., Boelle P.Y., Becquemont L, Poupon R: Erythromycin infusion prior to endoscopy for acute upper gastrointestinal bleeding: a randomized, controlled, double-blind trial. Am. J. Gastroenterol. 101, 1211–1215 (2006)

8. Carsenti-Dellamonica H., Galimand M., Vandenbos F., Pradier C., Roger P.M., Dunais B., Sabah M., Mancini G., Dellamonica P.: In vitro selection of mutants of Streptococcus pneumoniae resistant to macrolides and linezolid: relationship with susceptibility to penicillin G and macrolides. J. Antimicrob. Chemother. 56, 633–642 (2005)

9. Catnach S.M., Fairclough P.D., Trembath R.C., O’Donnell L.J.D., McLean A.M., Law P.A., Wickham J.E.A.: Effect of oral erythromycin on gallbladder motility in normal and gallstone subjects. Gastroenterology, 102, 2071–2076 (1992)

10. Cheng J., Shah Y.M., Gonzalez F.J.: Pregnane X receptor as a target for treatment of inflammatory bowel disorders. Trends Pharmacol. Sci. 33, 323–330 (2012)

11. Cherrill D.A., Stote R.M., Birge J.R., Singer I.: Demeclocycline treatment in the syndrome of inappropriate antidiuretic hormone secretion. Ann. Int. Med. 83, 654–656 (1975)

12. Chini P., Toskes P.P., Waseem S., Hou W., McDonald R., Moshiree B.: Effect of azithromycin on small bowel motility in patients with gastrointestinal dysmotility. Scand. J. Gastroenterol. 47, 422–427 (2012)

13. Choi Y., Suh Y.H. i wsp.: Minocycline attenuates neuronal cell death and improves cognitive impairment in Alzheimer’s disease models. Neuropsychopharmacology, 32, 2393–2404 (2007)

14. Coffin B., Valleur P. i wsp.: Erythromycin improves the quality of EGD in patients with acute upper GI bleeding: a randomized controlled study. Gastrointest. Endosc. 56, 174–179 (2002)

15. Curry J.I., Lander T.D., Stringer M.D.: Review article: erythromycin as a prokinetic agent in infants and children. Aliment. Pharmacol. Ther. 15, 595–603 (2001)

16. Dall’Antonia M., Wilks M., Coen P.G., Bragman S., Millar M.R.: Erythromycin for prokinetics: imprudent prescribing? Crit. Care, 10, 112 (2006)

17. De Francesco E.M., Bonuccelli G., Maggiolini M., Sotgia F., Lisanti M.P.: Vitamin C and Doxycycline: A synthetic lethal combination therapy targeting metabolic flexibility in cancer stem cells (CSCs). Oncotarget, 40, 67269–67286 (2017)

18. De Francesco E.M., Maggiolini M., Tanowitz H.B., Sotgia F., Lisanti M.P.: Targeting hypoxic cancer stem cells (CSCs) with Doxycycline: Implications for optimizing anti-angiogenic therapy. Oncotarget, 34, 56126–56142 (2017)

19. Demoly P., Gueron B., Annunziata K., Adamek L., Walters R.D.: Update on asthma control in five European countries: results
of a 2008 survey. Eur. Respir. Rev. 116, 150–157 (2010)

20. Depoortere I., Peeters T.L., Matthijs G., Vantrappen G.: Macrolides antibiotics are motilin receptor agonists. Hepatogastroenterology, 35, 198 (1988)

21. Doherty W.L., Winter B.: Prokinetic agents in critical care. Crit. Care, 7, 206–208 (2003)

22. Fox C., Dingman A., Derugin N., Wendland M.F., Manabat C., Ji S., Ferriero D.M., Vexler Z.S.: Minocycline confers early but transient protection in the immature brain following focal cerebral ischemia-reperfusion. J. Cereb. Blood Flow Metab. 25, 1138–1149 (2005)

23. Frossard J.L., Spahr L., Queneau P.E., Giostra E., Burckhardt B., Ory G., De Saussure P., Armenian B., De Peyer R., Hadengue A.: Erythromycin intravenous bolus infusion in acute upper gastrointestinal bleeding: a randomized, controlled, double blind trial. Gastroenterology, 123, 17–23 (2002)

24. German-Fattal M.: Fusafungine, an antimicrobial with anti-inflammatory properties in respiratory tract infections – review and recent advances in cellular and molecular activity. Clin. Drug Investig. 21, 653–670 (2001)

25. Goh K.P.: Management of hyponatremia. Am. Fam. Physician, 69, 2387–2394 (2004)

26. Golub L.M., Goodson J.M., Lee H.M., Vidal A.M., McNamara T.F., Ramamurthy N.S.: Tetracyclines Inhibit Tissue Collagenases: Effects of Ingested Low-Dose and Local Delivery Systems. J. Periodontol. 56, 93–97 (1985)

27. Golub L.M., Lee H.M., Ryan M.E., Giannobile W.V., Payne J., Sorsa T.: Tetracyclines inhibit connective tissue breakdown by multiple non-antimicrobial mechanisms. Adv. Dent. Res. 12, 12–26 (1998)

28. Golub L.M., McNamara T.F., Ryan M.E., Kohut B., Blieden T., Payonk G., Sipos T., Baron H.J.: Adjunctive treatment with subantimicrobial doses of doxycycline: effects on gingival fluid collagenase activity and attachment loss in adult periodontitis. J. Clin. Periodontol. 28, 146–156 (2001)

29. Gu Y., Lee H.M., Sorsa T., Simon S.R., Golub L.M.: Doxycycline inhibits mononuclear cell-mediated connective tissue breakdown. FEMS Immunol. Med. Microbiol. 58, 218–225 (2010)

30. Hahn D.L., Grasmick M., Hetzel S., Yale S.: Azithromycin for bronchial asthma in adults: an effectiveness trial. J. Am. Board Fam. Med. 25, 442–459 (2012)

31. Hahn D.L., Plane M.B., Mahdi O.S., Byrne G.I.: Secondary Outcomes of a Pilot Randomized Trial of Azithromycin Treatment for Asthma. PLoS Clin. Trials, 2, e11, (2006)

32. Hatipoglu U., Rubinstein I.: Low-dose, long-term macrolide therapy in asthma: An overview. Clin. Mol. Allergy, 2, 4 (2004)

33. Hu Y.Y., Xu J., Zhang M., Wang D., Li L., Li W.B.: Ceftriaxone modulates uptake activity of glial glutamate transporter-1 against global brain ischemia in rats. J. Neurochem. 132, 194–205 (2015)

34. Itoh Z., Nakaya M., Suzuki T., Arai H., Wakabayashi K.: Erythromycin mimics exogenous motilin in gastrointestinal contractile activity in the dog. Am. J. Physiol. 247, G688–694 (1984)

35. Jalal F.Y., Yang Y., Thompson J.F., Roitbak T., Rosenberg G.A.: Hypoxia-induced neuroinflammatory white-matter injury redu
ced by minocycline in SHR/SP. J. Cereb. Blood Flow Metab. 35, 1145–1153 (2015)

36. Janssens J., Vantrappen G., Annese V., Peeters T.L., Tijskens G., Rekoumis G.: Effect of erythromycin on LES function and oesophageal body contractility. Gastroenterology, 98, A64 (1990)

37. Jesionowska A., Cecerska-Heryć E., Marczuk N., Safronow K., Dołęgowska B.: Kwas lizofosfatydowy w nowotworach złośliwych. Postępy Biochemii, 4, 381–387 (2015)

38. Jiang Z.D., Ke S., DuPont H.L.: Rifaximin-induced alteration of virulence of diarrhea-producing Escherichia coli and Shigella sonnei. Int. J. Antimicrob. Agents, 35, 278–281 (2010)

39. John R., Brazier J.S.: Antimicrobial susceptibility of polymerase chain reaction ribotypes of Clostridium difficile commonly isolated from symptomatic hospital patients in the UK. J. Hosp. Infect. 61, 11–14 (2005)

40. Johnston S.L., Chauhan A. i wsp.: Azithromycin for Acute Exacerbations of Asthma: The AZALEA Randomized Clinical Trial. JAMA Intern. Med. 176, 1630–1637 (2016)

41. Kajander K., Myllyluoma E., Kyrönpalo S., Rasmussen M., Sipponen P., Mattila I., Seppänen-Laakso T., Vapaatalo H., Oresic M.,
Korpela R.: Elevated pro-inflammatory and lipotoxic mucosal lipids characterise irritable bowel syndrome. World J. Gastroenterol. 15, 6068–6074 (2009)

42. Kalambokis G.N., Mouzaki A., Rodi M., Pappas K., Fotopoulos A., Xourgia X., Tsianos E.V.: Rifaximin improves systemic hemodynamics and renal function in patients with alcohol-related cirrhosis and ascites. Clin. Gastroenterol. Hepatol. 10, 815–818 (2012)

43. Kew K.M., Undela K., Kotortsi I., Ferrara G.: Macrolides for chronic asthma. Cochrane Database Syst. Rev. 9, CD002997 (2015)

44. Kliewer S.A., Goodwin B., Willson T.M.: The nuclear pregnane X receptor: a key regulator of xenobiotic metabolism. Endocr. Rev. 23, 687–702 (2002)

45. Krzyżanowska W., Pomierzy B., Budziszewska B., Filip M., Pera J.: N-Acetylcysteine and Ceftriaxone as Preconditioning Strategies in Focal Brain Ischemia: Influence on Glutamate Transporters Expression. Neurotox. Res. 29, 539–550 (2016)

46. Ksiądzyna D.: Zaburzenia czynnościowe żołądka i dwunastnicy (w) Zaburzenia czynnościowe przewodu pokarmowego, red.
L. Paradowski, Cornetis, Wrocław, 2012, s. 89–104

47. Ksiądzyna D.: Wpływ innych chorób na czynność przewodu pokarmowego – gastropareza (w) Zaburzenia czynnościowe przewodu pokarmowego, red. L. Paradowski, Cornetis, Wrocław, 2012, s. 213–227

48. Lee G.J., Lim J.J., Hyun S.: Minocycline treatment increases resistance to oxidative stress and extends lifespan in Drosophila via FOXO. Oncotarget, 50, 87878–87890 (2017)

49. Lee S.G., Su Z.Z., Emdad L., Gupta P., Sarkar D., Borjabad A., Volsky D.J., Fisher P.B.: Mechanism of ceftriaxone induction of excitatory amino acid transporter-2 expression and glutamate uptake in primary human astrocytes. J. Biol. Chem. 283, 13116–13123 (2008)

50. Lehtola J., Jauhonen P., Kesaniemi A., Wikberg R., Gordin A.: Effect of erythromycin on the oro-caecal transit time in man. Eur. J. Clin. Pharmacol. 39, 555–558, (1990)

51. Leung T.C.H., Lui C.N.P., Chen L.W., Yung W.H., Chan Y.S., Yung K.K.L.: Ceftriaxone ameliorates motor deficits and protects dopaminergic neurons in 6-hydroxydopamine-lesioned rats. ACS Chem. Neurosci. 3, 22–30 (2012)

52. Leung W.K., Chan F.K.L., Fung S.S.L., Wong M.Y., Sung J.J.Y.: Effff ect of oral erythromycin on gastric and small bowel transit time of capsule endoscopy. World J. Gastroenterol. 11, 4865–4868 (2005)

53. Lewerenz J., Albrecht P., Tien M.L., Henke N., Karumbayaram S., Kornblum H.I., Wiedau-Pazos M., Schubert D., Maher P., Methner A.: Induction of Nrf2 and xCT are involved in the action of the neuroprotective antibiotic ceftriaxone in vitro. J. Neurochem. 111, 332–243 (2009)

54. Liebregts T., Holtman G. i wsp.: Immune activation in patients with irritable bowel syndrome. Gastroenterology, 132, 913–920 (2007)

55. Lund V.J., Grouin J.M., Eccles R., Bouter C., Chabolle F.: Efficacy of fusafungine in acute rhinopharyngitis: a pooled analysis. Rhinology, 42, 207–212 (2004)

56. Marek T., Baniukiewicz A., Wallner G., Rydzewska G., Dąbrowski A.: Wytyczne postępowania w krwawieniu z górnego odcinka przewodu pokarmowego pochodzenia nieżylakowego. Prz. Gastroenterol. 3, 1–22 (2008)

57. Matsumoto T., Uchiumi T., Monji K., Yagi M., Setoyama D., Amamoto R., Matsushima Y., Shiota M., Eto M., Kang D.: Doxycycline induces apoptosis via ER stress selectively to cells with a cancer stem cell-like properties: importance of stem cell plasticity. Oncogenesis, 11, 397 (2017)

58. McGuire J.M., Bunch R.L., Anderson R.C., Boaz H.E., Flynn E.H., Powell H.M., Smith J.W.: „Ilotycin”, a new antibiotic. Antibiot. Chemother. 2, 281 (1952)

59. Menzel M., Akbarshahi H., Tufvesson E., Persson C., Bjermer L., Uller L.: Azithromycin augments rhinovirus-induced IFNβ via cytosolic MDA5 in experimental models of asthma exacerbation. Oncotarget, 19, 31601–31611 (2017)

60. Mertens V., Blondeau K., Pauwels A., Farre R., Vanaudenaerde B., Vos R., Verleden G., Van Raemdonck D.E., Dupont L.J., Sifrim D.: Azithromycin reduces gastroesophageal reflux and aspiration in lung transplant recipients. Dig. Dis. Sci. 54, 972–979 (2009)

61. Miell J., Dhanjal P., Jamookeeah C.: Evidence for the use of demeclocycline in the treatment of hyponatraemia secondary to SIADH: a systematic review. Int. J. Clin. Pract. 69, 1396–1417 (2015)

62. Min Y., Li F. i wsp.: Minocycline-Suppression of Early Peripheral Inflammation Reduces Hypoxia-Induced Neonatal Brain Injury. Front. Neurosci. 11, 511 (2017)

63. Moini-Zanjani T., Ostad S.N., Labibi F., Ameli H., Mosaffa N., Sabetkasaei M.: Minocycline Effects on IL-6 Concentration in Macrophage and Microglial Cells in a Rat Model of Neuropathic Pain. Iran. Biomed. J. 20, 273–279 (2016)

64. Mullany P., Wilks M., Tabaqchali S.: Transfer of macrolide-lincosamide – streptogramin B (MLS) resistance in Clostridium difficile is linked to a gene homologous with toxin A and is mediated by a conjugative transposon Tn5398. J. Antimicrob. Chemother. 35, 305–315 (1995)

65. Peeters T., Matthijs G., Depoortere I., Cachet T., Hoogmartens J., Vantrappen G.: Erythromycin is a motilin receptor agonist. Am. J. Physiol. 257, G470–G474 (1989)

66. Peiris-Pagès M., Sotgia F., Lisanti M.P.: Doxycycline and therapeutic targeting of the DNA damage response in cancer cells: old drug, new purpose. Oncoscience, 8, 696–699 (2015)

67. Pietrzak A., Bartnik W., Szczepkowski M., Krokowicz P., Dziki A., Reguła J., Wallner G.: Polish interdisciplinary consensus on diagnostics and treatment of colonic diverticulosis. Pol. Przeg. Chir. 87, 203–220 (2015)

68. Pilot M.A., Ritchie H.D., Thompson H., Zara G.P.: Alterations in gastrointestinal motility associated with erythromycin. Br.
J. Pharmacol. 81: 168P (1984)

69. Pimentel M., Forbes W.P. i wsp.: Rifaximin therapy for patients with irritable bowel syndrome without constipation. N. Engl.
J. Med. 364, 22–32 (2011)

70. Pimentel M.: Review article: potential mechanisms of action of rifaximin in the management of irritable bowel syndrome with diarrhoea. Aliment. Pharmacol. Ther. 43 Suppl. 1, 37–49 (2016)

71. Pimentel M., Cash B.D., Limbo A., Wolf R.A., Israel R.J., Schoenfeld P.: Repeat rifaximin for irritable bowel syndrome: no clinical significant changes in stool microbial antibiotic sensitivity. Dig. Dis. Sci. 62, 2455–2463 (2017)

72. Qin Y., Zhou H.G. i wsp.: Doxycycline reverses epithelial-to-mesenchymal transition and suppresses the proliferation and metastasis of lung cancer cells. Oncotarget, 38, 40667–40679 (2015)

73. Reiter J., Demirel N., Mendy A., Gasana J., Vieira E.R., Colin A.A., Quizon A., Forno E.: Macrolides for the long-term management of asthma – a meta-analysis of randomized clinical trials. Allergy, 68, 1040–1049 (2013)

74. Richards R.D., Davenport K.G., Hurm K.D., Wimbish W.R., McCallum R.W.: Acute and chronic treatment of gastroparesis with erythromycin. Gastroenterology, 98, A385 (1990)

75. Rifkin B.R., Vernillo A.T., Golub L.M.: Blocking Periodontal Disease Progression by Inhibiting Tissue-Destructive Enzymes: A Potential Therapeutic Role for Tetracyclines and Their Chemically-Modified Analogs. Journal of Periodontology, 64, 819–827 (1993)

76. Rohof W.O., Bennink R.J., Ruigh A.A., Hirsch D.P., Zwinderman A.H., Boeckxstaens G.E.: Effect of azithromycin on acid reflux, hiatus hernia and proximal acid pocket in the postprandial period. Gut, 61, 1670–1677 (2012)

77. Rothstein J.D., Fisher P.B. i wsp.: Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature, 7021, 73–77 (2005)

78. Ruzza P., Sechi G. i wsp.: Ceftriaxone blocks the polymerization of α-synuclein and exerts neuroprotective effects in vitro. ACS Chem. Neurosci. 5, 30–38 (2014)

79. Sarna S.K., Lee M.B. i wsp.: Effects of erythromycin on human gastrointestinal motor activity in the fed and fasted states. Gastroenterology, 96, A440 (1989)

80. Scholz R., Sobotka M., Caramoy A., Stempfl A., Moehle C., Langmann T.: Minocycline counter-regulates pro-inflammatory microglia responses in the retina and protects from degeneration. J. Neuroinflammation, 12: 209 (2015)

81. Secko D.: Antibiotics that protect the brain. CMAJ 172, 467–468 (2005)

82. Sherlock M., Thompson C.J.: The syndrome of inappropriate antidiuretic hormone: current and future management options. Eur. J. Endocrinol. 162 Suppl. 1, S13–88 (2010)

83. Shlopov B.V., Stuart J.M., Gumanovskaya M.L., Hasty K.A.: Regulation of cartilage collagenase by doxycycline. J. Rheumatol. 28, 835–842 (2001)

84. Smith G.N. Jr., Yu L.P. Jr., Brandt K.D., Capello W.N.: Oral administration of doxycycline reduces collagenase and gelatinase activities in extracts of human osteoarthritic cartilage. J. Rheumatol. 25, 532–535 (1998)

85. Sorsa T., Tervahartiala T., Leppilahti J., Hernandez M., Gamonal J., Tuomainen A.M., Lauhio A., Pussinen P.J., Mäntylä P.: Collagenase-2 (MMP-8) as a point-of-care biomarker in periodontitis and cardiovascular diseases. Therapeutic response to non-antimicrobial properties of tetracyclines. Pharmacol. Res. 63, 108–113 (2011)

86. Spasovski G., Nagler E. i wsp.: Clinical practice guidelines on diagnosis and treatment of hyponatremia. Eur. J. Endocrinol. 170, G1–47 (2014)

87. Stallinger S., Eller N., Högenauer C.: Non-interventional study evaluating efficacy and tolerability of rifaximin for treatment of uncomplicated diverticular disease. Wiener Klin. Wochenschr. 126, 9–14 (2014)

88. Sturm A., Holtmann G., Goebell H., Gerken G.: Prokinetics in patients with gastroparesis: a systematic analysis. Digestion, 60, 422–427 (1999)

89. Sy-Cordero A.A., Pearce C.J., Oberlies N.H.: Revisiting the enniatins: a revive of their isolation, biosynthesis, structure determination, and biological activities. J. Antibiot. 65, 541–549 (2012)

90. Talley N.J., Verlinden M., Geenen D.J., Hogan R.B., Riff D., McCallum R.W., Mack R.J.: Effects of a motilin receptor agonist (ABT-229) on upper gastrointestinal symptoms in type 1 diabetes mellitus: a randomized, double blind, placebo controlled trial. Gut, 49, 395–401 (2001)

91. Tang X., Wang X., Zhao Y.Y., Curtis J.M., Brindley D.N.: Doxycycline attenuates breast cancer related inflammation by decreasing plasma lysophosphatidate concentrations and inhibiting NF-κB activation. Mol. Cancer, 16, 36 (2017)

92. Vezina C., Kudelski A., Sehgal S.N.: Rapamycin (AY-22, 989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. J. Antibiot. 28, 721–726 (1975)

93. Wang Z., Nong J., Shultz R.B., Zhang Z., Kim T., Tom V.J., Ponnappan R.K., Zhong Y.: Local delivery of minocycline from metal ion-assisted self-assembled complexes promotes neuroprotection and functional recovery after spinal cord injury. Biomaterials, 112, 62–71 (2017)

94. Warny M., Pepin J., Fang A., Killgore G., Thompson A., Brazier J., Frost E., McDonald L.C.: Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet, 366, 1079–1084 (2005)

95. Webley W.C., Hahn D.L.: Infection-mediated asthma: etiology, mechanisms and treatment options, with focus on Chlamydia pneumoniae and macrolides. Respiratory Res. 18, 98 (2017)

96. Xu X., Gaggar A. i wsp.: Doxycycline improves clinical outcomes during cystic fibrosis exacerbations. Eur. Respir. J. 49, pii: 1601102 (2017)

97. Zatmann T.F., Hall J.E., Harmer M.: Gastric residual volume in children: a study comparing efficiency of erythromycin and metoclopramide as prokinetic agents. Br. J. Anaesth. 86, 869–871 (2001)

98. Zhang L., Xu L., Zhang F., Vlashi E.: Doxycycline inhibits the cancer stem cell phenotype and epithelial-to-mesenchymal transition in breast cancer. Cell Cycle, 16, 737–745 (2017)

99. Zhong W., Yang C. i wsp.: Doxycycline inhibits breast cancer EMT and metastasis through PAR-1/NF-κB/miR-17/E-cadherin pathway. Oncotarget, 62, 104855-104866 (2017)

EXTRA FILES

COMMENTS